Clostridium difficile on the transplantation radar

Transplantation

Volumn 93, Issue 10, 2012, Pages 974-975

  Peltekian, Kevork M ^a,b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; FIDAXOMICIN; IMMUNOGLOBULIN; METRONIDAZOLE; MONOCLONAL ANTIBODY; NITAZOXANIDE; PROBIOTIC AGENT; RIFAXIMIN; THYMOCYTE ANTIBODY; VANCOMYCIN;

ADJUVANT THERAPY; AGE DISTRIBUTION; BACTERIAL SPORE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; CLOSTRIDIUM DIFFICILE INFECTION; COLON RESECTION; DIARRHEA; DISEASE SEVERITY; DRUG CHOICE; DRUG EFFICACY; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT REJECTION; HEALTH CARE FACILITY; HOST SUSCEPTIBILITY; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INFECTION RATE; LEUKOCYTOSIS; MORBIDITY; MORTALITY; NOTE; ORGAN TRANSPLANTATION; OUTCOME ASSESSMENT; PANCOLITIS; PRIORITY JOURNAL; PSEUDOMEMBRANOUS COLITIS; RECURRENT INFECTION; RISK FACTOR; TREATMENT DURATION;

CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COLITIS; DIARRHEA; FEMALE; HUMANS; MALE; ORGAN TRANSPLANTATION;

EID: 84861094389     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182510939     Document Type: Note

References (15)

1. Bartlett JG. Clostridium difficile: Progress and challenges. Ann New York Acad Sci 2010; 1213: 62.
2. Khanna S, Pardi DS. The growing incidence and severity of Clostridium difficile infection in inpatient and outpatient settings. Expert Rev Gastroenterol Hepatol 2010; 4: 409.
3. Karas JA, Enoch DA, Aliyu SH. A review of mortality due to Clostridium difficile infection. J Infect 2010; 61: 1.
4. Karen CC, John GB. Biology of Clostridium difficile: Implications for epidemiology and diagnosis. Annu Rev Microbiol 2011; 65: 501.
5. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007; 357: 2601.
6. Boutros M, Al-Shaibi M, Chan G, et al. Clostridium difficile colitis: Increasing incidence, risk factors and outcomes in solid organ transplant recipients. Transplantation 2012; 93: 1051.
7. West M, Pirenne J, Chavers B, et al. Clostridium difficile colitis after kidney and kidney-pancreas transplantation. Clin Transplant 1999; 13: 318.
8. Keven K, Basu A, Re L, et al. Clostridium difficile colitis in patients after kidney and pancreas-kidney transplantation. Transpl InfectDis 2004; 6: 10.
9. Stelzmueller I, Goegele H, Biebl M, et al. Clostridium difficile colitis in solid organ transplantationVA single-center experience. Dig Dis Sci 2007; 52: 3231.
10. Rochon C, Kardashian A, Mahadevappa B, et al. Liver graft failure and hyperbilirubinemia in liver transplantation recipients after Clostridium difficile infection. Transplant Proc 2011; 43: 3819.
11. Gunderson CC, Gupta MR, Lopez F, et al. Clostridium difficile colitis in lung transplantation. Transpl Infect Dis 2008; 10: 245.
12. Musgrave CR, Bookstaver PB, Sutton SS, et al. Use of alternative or adjuvant pharmacologic treatment strategies in the prevention and treatment of Clostridium difficile infection. Int J Infect Dis 2011; 15: E438.
13. Butala P, Divino CM. Surgical aspects of fulminant Clostridium difficile colitis. Am J Surg 2010; 200: 131.
14. van Nispen tot Pannerden CM, Verbon A, Kuipers EJ. Recurrent Clostridium difficile infection: What are the treatment options? Drugs 2011; 71: 853.
15. Barbut F, Jones G, Eckert C. Epidemiology and control of Clostridium difficile infections in healthcare settings: An update. Curr Opin Infect Dis 2011; 24: 370.